Bortezomib, Rituximab, Dexamethasone — Competitive Intelligence Brief

Bortezomib, Rituximab, Dexamethasone (Bortezomib, Rituximab, Dexamethasone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proteasome inhibitor. Area: Oncology.

phase 2 Proteasome inhibitor 20S proteasome Oncology Small molecule

Target snapshot

Bortezomib, Rituximab, Dexamethasone (Bortezomib, Rituximab, Dexamethasone) — Meletios A. Dimopoulos. Proteasome inhibitor

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bortezomib, Rituximab, Dexamethasone TARGET	Bortezomib, Rituximab, Dexamethasone	Meletios A. Dimopoulos	phase 2	Proteasome inhibitor	20S proteasome
Drug: Carfilzomib + Dexamethasone	Drug: Carfilzomib + Dexamethasone	Amgen	marketed	Proteasome inhibitor + corticosteroid combination	20S proteasome (carfilzomib); glucocorticoid receptor (dexamethasone)
Drug: Carfilzomib + Lenalidomide + Dexamethasone	Drug: Carfilzomib + Lenalidomide + Dexamethasone	Amgen	marketed	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
VBMCP/VBAD/Velcade	VBMCP/VBAD/Velcade	PETHEMA Foundation	phase 3	Proteasome inhibitor	20S proteasome
R2: Lenalidomide + ixazomib maintenance	R2: Lenalidomide + ixazomib maintenance	University of Leeds	phase 3	Immunomodulatory agent + proteasome inhibitor combination	Cereblon (lenalidomide); 20S proteasome (ixazomib)
Carfilzomib Lenalidomide Dexamethasone	Carfilzomib Lenalidomide Dexamethasone	European Myeloma Network B.V.	phase 3	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); Cereblon/E3 ubiquitin ligase (lenalidomide); Glucocorticoid receptor (dexamethasone)
lenalidomide, bortezomib and dexamethasone	lenalidomide, bortezomib and dexamethasone	National Heart, Lung, and Blood Institute (NHLBI)	phase 3	Combination therapy: immunomodulatory agent, proteasome inhibitor, and corticosteroid	Multiple targets: cereblon (lenalidomide), 20S proteasome (bortezomib), glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proteasome inhibitor class)

1. Millennium Pharmaceuticals, Inc. · 2 drugs in this class
2. Meletios A. Dimopoulos · 1 drug in this class
3. National Cancer Institute (NCI) · 1 drug in this class
4. PETHEMA Foundation · 1 drug in this class
5. Pfizer · 1 drug in this class
6. Shilpa · 1 drug in this class
7. Telik · 1 drug in this class
8. European Myeloma Network B.V. · 1 drug in this class
9. University of Arkansas · 1 drug in this class